<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392457</url>
  </required_header>
  <id_info>
    <org_study_id>R01 HD15788 - 234</org_study_id>
    <nct_id>NCT00392457</nct_id>
  </id_info>
  <brief_title>Investigating the Regulation of Reproductive Hormones in Adult Men</brief_title>
  <official_title>Feedback Control of FSH Secretion in the Human Male</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <brief_summary>
    <textblock>
      The purpose of the research study is to learn more about the regulation of reproductive
      hormones in adult men. We would like to understand what role testosterone and estradiol play
      in controlling the release of LH (lutenizing hormone) and FSH (follicle stimulating hormone).
      Testosterone and estradiol come from the testes, and LH and FSH are released from a gland in
      the head called the pituitary.

      Men involved in the study will have detailed evaluations that involve overnight stays in the
      hospital and frequent blood sampling. The men in the study will also be receiving medications
      that affect the levels of various hormones in the body. This will allow the researchers to
      learn how various hormones influence each other. Men that participate in the study will
      receive medical evaluations and monetary compensation. Information gathered from this study
      will help in the development of new treatments for infertility and potentially new hormonal
      forms of contraception.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the United States 10-15% couples seek evaluation for infertility, of whom a male factor is
      identified in approximately 50% of cases. To date, however, most infertility research has
      focused on the female partner and in the majority of instances the etiology of male
      infertility remains poorly understood with inconsistent elevation in FSH levels. Given that
      spermatogenesis is highly dependent on FSH secretion, this project will focus on delineating
      the feedback control of FSH in the human male. Such studies, although difficult to perform in
      the human, are critical to understanding not only the pathophysiology of male infertility,
      but also to determining the feasibility of hormonal approaches to male contraception. In this
      protocol, studies of normal, GnRH-deficient and agonadal men employing reversible sex steroid
      ablation, physiologic sex steroid replacement and manipulation of the GnRH input to the
      pituitary will permit the non-steroidal, sex steroid, and GnRH-dependent components of FSH
      regulation to be selectively elucidated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1995</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum hormone levels</measure>
    <time_frame>Baseline, Day 3, and Day 6</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Kallmann Syndrome</condition>
  <condition>Hypogonadism</condition>
  <condition>Gonadal Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <description>loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gonadotropin releasing hormone (GnRH)</intervention_name>
    <description>Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 18 to 50 years

          -  In good health

          -  On no medications

        Exclusion Criteria:

        Subjects will not be enrolled in this study if there is a history of:

          -  Liver disease or if screening blood tests demonstrate abnormal liver function tests

          -  Excessive alcohol consumption

          -  Illicit drug use

          -  Severe drug allergy

          -  Use of any concomitant medications

          -  Peptic ulcer disease or gastritis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William F Crowley, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massgeneral.org/reproendo/pages/reu_study_subject.htm</url>
    <description>Clinical research studies of the Reproductive Endocrine Unit at the Massachusetts General Hospital. Click here for more information about this study: Feedback Control of FSH Secretion in the Human Male</description>
  </link>
  <reference>
    <citation>Howards SS. Treatment of male infertility. N Engl J Med. 1995 Feb 2;332(5):312-7. Review.</citation>
    <PMID>7816068</PMID>
  </reference>
  <reference>
    <citation>Ying SY. Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev. 1988 May;9(2):267-93. Review.</citation>
    <PMID>3136011</PMID>
  </reference>
  <reference>
    <citation>Khoury RH, Wang QF, Crowley WF Jr, Hall JE, Schneyer AL, Toth T, Midgley AR Jr, Sluss PM. Serum follistatin levels in women: evidence against an endocrine function of ovarian follistatin. J Clin Endocrinol Metab. 1995 Apr;80(4):1361-8.</citation>
    <PMID>7714112</PMID>
  </reference>
  <reference>
    <citation>Hayes FJ, Hall JE, Boepple PA, Crowley WF Jr. Clinical review 96: Differential control of gonadotropin secretion in the human: endocrine role of inhibin. J Clin Endocrinol Metab. 1998 Jun;83(6):1835-41. Review.</citation>
    <PMID>9626105</PMID>
  </reference>
  <reference>
    <citation>Santen RJ. Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men? J Clin Invest. 1975 Dec;56(6):1555-63.</citation>
    <PMID>1104659</PMID>
  </reference>
  <reference>
    <citation>Winters SJ, Janick JJ, Loriaux DL, Sherins RJ. Studies on the role of sex steroids in the feedback control of gonadotropin concentrations in men. II. Use of the estrogen antagonist, clomiphene citrate. J Clin Endocrinol Metab. 1979 Feb;48(2):222-7.</citation>
    <PMID>372203</PMID>
  </reference>
  <reference>
    <citation>Matsumoto AM, Bremner WJ. Modulation of pulsatile gonadotropin secretion by testosterone in man. J Clin Endocrinol Metab. 1984 Apr;58(4):609-14.</citation>
    <PMID>6421864</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Whitcomb RW, O'Dea LS, Longcope C, Schoenfeld DA, Crowley WF Jr. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab. 1991 Sep;73(3):609-20.</citation>
    <PMID>1908484</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, O'Dea LS, Whitcomb RW, Crowley WF Jr. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab. 1991 Sep;73(3):621-8.</citation>
    <PMID>1908485</PMID>
  </reference>
  <reference>
    <citation>Bagatell CJ, Dahl KD, Bremner WJ. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol. J Androl. 1994 Jan-Feb;15(1):15-21.</citation>
    <PMID>8188534</PMID>
  </reference>
  <reference>
    <citation>Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab. 1996 Apr;81(4):1401-5.</citation>
    <PMID>8636341</PMID>
  </reference>
  <reference>
    <citation>Majumdar SS, Mikuma N, Ishwad PC, Winters SJ, Attardi BJ, Perera AD, Plant TM. Replacement with recombinant human inhibin immediately after orchidectomy in the hypophysiotropically clamped male rhesus monkey (Macaca mulatta) maintains follicle-stimulating hormone (FSH) secretion and FSH beta messenger ribonucleic acid levels at precastration values. Endocrinology. 1995 May;136(5):1969-77.</citation>
    <PMID>7720645</PMID>
  </reference>
  <reference>
    <citation>Culler MD, Negro-Vilar A. Passive immunoneutralization of endogenous inhibin: sex-related differences in the role of inhibin during development. Mol Cell Endocrinol. 1988 Aug;58(2-3):263-73.</citation>
    <PMID>3145231</PMID>
  </reference>
  <reference>
    <citation>Veldhuis JD, Johnson ML. Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection. Am J Physiol. 1986 Apr;250(4 Pt 1):E486-93.</citation>
    <PMID>3008572</PMID>
  </reference>
  <reference>
    <citation>Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 1982 Jan-Feb;23(1-2):1-36. Review.</citation>
    <PMID>6276122</PMID>
  </reference>
  <reference>
    <citation>Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, Stevens DA. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984 Nov;144(11):2150-3.</citation>
    <PMID>6093722</PMID>
  </reference>
  <reference>
    <citation>Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987 Sep 24;317(13):812-8. Review.</citation>
    <PMID>3306384</PMID>
  </reference>
  <reference>
    <citation>Van Tyle JH. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343-73. Review.</citation>
    <PMID>6151171</PMID>
  </reference>
  <reference>
    <citation>Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984 Mar;86(3):503-13.</citation>
    <PMID>6319220</PMID>
  </reference>
  <reference>
    <citation>Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med. 1984 May;144(5):1069-70.</citation>
    <PMID>6324708</PMID>
  </reference>
  <reference>
    <citation>van Dijke CP, Veerman FR, Haverkamp HC. Anaphylactic reactions to ketoconazole. Br Med J (Clin Res Ed). 1983 Dec 3;287(6406):1673.</citation>
    <PMID>6315129</PMID>
  </reference>
  <reference>
    <citation>Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med. 1983 Jan 24;74(1B):80-5.</citation>
    <PMID>6129799</PMID>
  </reference>
  <results_reference>
    <citation>Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF Jr, Hayes FJ. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab. 2008 Mar;93(3):784-91. Epub 2007 Dec 11.</citation>
    <PMID>18073301</PMID>
  </results_reference>
  <results_reference>
    <citation>Boepple PA, Hayes FJ, Dwyer AA, Raivio T, Lee H, Crowley WF Jr, Pitteloud N. Relative roles of inhibin B and sex steroids in the negative feedback regulation of follicle-stimulating hormone in men across the full spectrum of seminiferous epithelium function. J Clin Endocrinol Metab. 2008 May;93(5):1809-14. doi: 10.1210/jc.2007-2450. Epub 2008 Feb 12.</citation>
    <PMID>18270253</PMID>
  </results_reference>
  <results_reference>
    <citation>Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF Jr, Hayes FJ. The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab. 2008 Jul;93(7):2686-92. doi: 10.1210/jc.2007-2548. Epub 2008 Apr 29.</citation>
    <PMID>18445673</PMID>
  </results_reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <name_title>William F. Crowley Jr., MD</name_title>
    <organization>MGH</organization>
  </responsible_party>
  <keyword>Idiopathic Hypogonadotropic Hypogonadism</keyword>
  <keyword>Kallmann Syndrome</keyword>
  <keyword>Agonadal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Kallmann Syndrome</mesh_term>
    <mesh_term>Gonadal Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

